Skip to main content
Premium Trial:

Request an Annual Quote

Congenica Closes $50M Series C Funding Round

NEW YORK – Congenica said Monday that it has closed a $50 million Series C round of venture capital.

Tencent and Legal & General co-led the round, with participation from new investors Xeraya, Puhua Capital, and IDO Investments. Previous Congenica investors Parkwalk, Cambridge Innovation Capital, and Downing also contributed.

The Cambridge, UK-based developer of genomic analysis and clinical decision support technology said that the money would enable the firm to explore new "strategic and geographic capabilities," including a push into somatic cancer and wellness programs.

"This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets," Congenica CEO David Atkins said in a statement

Congenica also expects to accelerate integration of its technology platform into electronic health records systems and to automate genomic interpretation.

Congenica's technology "is designed to enable the delivery of personalized medicine at scale and be fully integrated into routine healthcare customers' clinical practice on a global basis," according to Ling Ge, chief European representative and general manager of China-based Tencent. "This represents a significant competitive advantage and the potential to bring genomic medicine into routine use across multiple disease areas driving healthcare systems internationally."

The firm most recently raised £23.3 million ($30.7 million) in a Series B round in 2019.

In 2018, Congenica signed an exclusive deal with the UK National Health Service to provide diagnostic decision support services to the NHS Genomic Medicine Service.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.